We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

900932:SSEShanghai Lujiazui Finance & Trade Zone Development Co., Ltd. Class B Analysis

Data as of 2026-09-11 - not real-time

$0.38

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Shanghai Lujiazui Finance & Trade Zone Development Co.,Ltd. is neutral at $0.3820, with no clear ordering between short and long averages. It has lost 1.0% over the past 30 days. RSI sits at 40.7, which reads as neutral, and MACD momentum is bearish. Watch $0.3810 as support and $0.3940 as the nearer resistance level.
Multiples put this in undervalued territory: 9.6 times earnings against the sector's 30.8. Sell-side targets cluster 32.2% above the current quote. Revenue is growing at 146.7% on a 7.7% profit margin. The 7.77% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 12.9%, a beta of 0.07 and a maximum drawdown of 21.7%, position sizing matters here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 6/10 conviction on the long call.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 0.40
  • MACD momentum is negative
  • Thin trading liquidity raises execution risk

Medium Term

1–3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 9.6 versus sector average of 30.8
  • Trading below the 200-day average of 0.40
  • Analyst targets imply +32.2% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 9.6 versus sector average of 30.8
  • Analyst targets imply +32.2% versus the current price
  • Revenue growth of +146.7%

Key Metrics & Analysis

Financial Health

Revenue Growth146.70%
Profit Margin7.72%
P/E Ratio9.6
ROE3.08%
ROA1.31%
Debt/Equity136.54
P/B Ratio0.5
Op. Cash Flow$11.1B
Free Cash Flow$13.5B
Industry P/E30.8

Technical Analysis

TrendNeutral
RSI40.7
Support$0.38
Resistance$0.39
MA 20$0.39
MA 50$0.38
MA 200$0.40
MACDBearish
VolumeStable
Fear & Greed Index92.66

Valuation

Fair Value$81.96
Target Price$0.50
Upside/Downside32.17%
GradeUndervalued
TypeValue
Dividend Yield7.77%

Risk Assessment

Beta0.07
Volatility12.87%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.